SQZ Biotechnologies Gross Profit 2020-2021 | SQZ

SQZ Biotechnologies gross profit from 2020 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
SQZ Biotechnologies Annual Gross Profit
(Millions of US $)
2020 $21
2019 $20
SQZ Biotechnologies Quarterly Gross Profit
(Millions of US $)
2021-09-30 $5
2021-06-30 $5
2021-03-31 $5
2020-12-31 $2
2020-09-30 $6
2020-06-30 $6
2020-03-31 $6
2019-09-30 $4
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.319B $0.021B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90